JP2010529193A5 - - Google Patents

Download PDF

Info

Publication number
JP2010529193A5
JP2010529193A5 JP2010512173A JP2010512173A JP2010529193A5 JP 2010529193 A5 JP2010529193 A5 JP 2010529193A5 JP 2010512173 A JP2010512173 A JP 2010512173A JP 2010512173 A JP2010512173 A JP 2010512173A JP 2010529193 A5 JP2010529193 A5 JP 2010529193A5
Authority
JP
Japan
Prior art keywords
cancer
disease
compound
salt
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010512173A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010529193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/007288 external-priority patent/WO2008154026A1/en
Publication of JP2010529193A publication Critical patent/JP2010529193A/ja
Publication of JP2010529193A5 publication Critical patent/JP2010529193A5/ja
Pending legal-status Critical Current

Links

JP2010512173A 2007-06-11 2008-06-11 置換ピラゾール化合物 Pending JP2010529193A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93406207P 2007-06-11 2007-06-11
US99047507P 2007-11-27 2007-11-27
PCT/US2008/007288 WO2008154026A1 (en) 2007-06-11 2008-06-11 Substituted pyrazole compounds

Publications (2)

Publication Number Publication Date
JP2010529193A JP2010529193A (ja) 2010-08-26
JP2010529193A5 true JP2010529193A5 (enExample) 2011-03-10

Family

ID=40130080

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512173A Pending JP2010529193A (ja) 2007-06-11 2008-06-11 置換ピラゾール化合物

Country Status (6)

Country Link
US (1) US20090029992A1 (enExample)
EP (1) EP2166849A4 (enExample)
JP (1) JP2010529193A (enExample)
AU (1) AU2008262291A1 (enExample)
CA (1) CA2683152A1 (enExample)
WO (1) WO2008154026A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6067226B2 (ja) 2009-03-13 2017-01-25 アジオス ファーマシューティカルズ， インコーポレイテッド 細胞増殖関連疾患のための方法および組成物
AR077292A1 (es) 2009-06-29 2011-08-17 Agios Pharmaceuticals Inc Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
ES2594402T3 (es) 2009-10-21 2016-12-20 Agios Pharmaceuticals, Inc. Métodos y composiciones para trastornos relacionados con la proliferación celular
AU2012236834B2 (en) 2011-03-28 2015-12-10 Mei Pharma, Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
HUE065700T2 (hu) 2011-05-03 2024-06-28 Agios Pharmaceuticals Inc Piruvát-kináz aktivátorok terápiában történõ alkalmazásra
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CA2860623A1 (en) 2012-01-06 2013-07-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US8916555B2 (en) 2012-03-16 2014-12-23 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
JP6385352B2 (ja) 2012-10-15 2018-09-05 アジオス ファーマシューティカルズ， インコーポレイテッド 治療化合物および組成物
AU2014287121B2 (en) * 2013-07-11 2018-11-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
SG11201600058XA (en) 2013-07-11 2016-02-26 Agios Pharmaceuticals Inc N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
LT3089971T (lt) 2014-01-01 2020-10-12 Medivation Technologies Llc Junginiai ir panaudojimo būdai
CA2942072C (en) 2014-03-14 2022-07-26 Agios Pharmaceuticals, Inc. Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
EP3179992B1 (en) 2014-08-11 2022-05-11 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
US20170231986A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor
US20170224819A1 (en) 2014-08-11 2017-08-10 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor
JP6450010B2 (ja) 2014-12-23 2019-01-09 アクシキン ファーマシューティカルズ インコーポレーテッド ３，５−ジアミノピラゾールキナーゼ阻害剤
PL3307271T3 (pl) 2015-06-11 2024-02-05 Agios Pharmaceuticals, Inc. Sposoby stosowania aktywatorów kinazy pirogronianowej
RS62829B1 (sr) 2015-10-15 2022-02-28 Servier Lab Kombinovana terapija za lečenje maligniteta
IL258684B2 (en) 2015-10-15 2023-04-01 Agios Pharmaceuticals Inc Combination therapy including an isocitrate dehydrogenase (1idh) inhibitor for use in the treatment of acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of 1idh
CA3039026A1 (en) * 2016-09-07 2018-03-15 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
WO2018106641A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
CN117860758A (zh) 2017-05-23 2024-04-12 梅制药公司 联合疗法
CN110573501B (zh) * 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN116514779B (zh) * 2022-05-06 2025-07-01 长沙晶易医药科技股份有限公司 2,4-二取代-5-氟嘧啶衍生物及其制备方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57203072A (en) * 1981-06-05 1982-12-13 Sankyo Co Ltd 4-anilinopyrimidine derivative, its preparation, antidepressant comprising it as active ingredient
EP1559778A1 (en) * 1991-08-07 2005-08-03 Albert Einstein College Of Medicine Of Yeshiva University Proliferation of hepatocyte precursors
US5453414A (en) * 1993-05-20 1995-09-26 Rohm And Haas Company 2-arylpyrimidines and herbicidal use thereof
DE69408750T2 (de) * 1993-08-26 1998-07-23 Ono Pharmaceutical Co 4-Aminopyrimidin Derivate
JPH10509708A (ja) * 1994-11-10 1998-09-22 コア セラピューティクス，インコーポレイティド プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物
DE19511562A1 (de) * 1995-03-29 1996-10-02 Hoechst Schering Agrevo Gmbh Cyclohexylamino- und alkoxy-Stickstoff-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5835725A (en) * 1996-10-21 1998-11-10 Cisco Technology, Inc. Dynamic address assignment and resolution technique
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
KR20010041015A (ko) * 1998-02-17 2001-05-15 윌리엄 제이. 리플린 항바이러스성 피리미딘 유도체
US20020065270A1 (en) * 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
JP4739632B2 (ja) * 2000-02-05 2011-08-03 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋのインヒビターとして有用なピラゾール組成物
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
WO2001079198A1 (en) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinase
DK1303495T3 (da) * 2000-07-24 2010-09-20 Krenitsky Pharmaceuticals Inc Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6638926B2 (en) * 2000-09-15 2003-10-28 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20020137755A1 (en) * 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
CA2432799C (en) * 2000-12-21 2008-08-19 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1389206B1 (en) * 2001-04-13 2006-09-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US6884804B2 (en) * 2001-05-16 2005-04-26 Vertex Pharmaceuticals Incorporated Inhibitors of Src and other protein kinases
MXPA03010961A (es) * 2001-05-31 2004-02-27 Vertex Pharma Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
US6825190B2 (en) * 2001-06-15 2004-11-30 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
MXPA04001088A (es) * 2001-08-03 2004-05-20 Vertex Pharma Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
JP4498741B2 (ja) * 2001-12-24 2010-07-07 アストラゼネカ アクチボラグ オーロラキナーゼ阻害剤としての置換キナゾリン誘導体
AU2003225800A1 (en) * 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
EP1485100B1 (en) * 2002-03-15 2010-05-05 Vertex Pharmaceuticals Incorporated Azinylaminoazoles as inhibitors of protein kinases
ES2289279T3 (es) * 2002-03-15 2008-02-01 Vertex Pharmaceuticals Incorporated Composiciones utiles como inhibidores de proteinquinasas.
ATE468336T1 (de) * 2002-03-15 2010-06-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
US6677337B2 (en) * 2002-03-19 2004-01-13 The Procter & Gamble Company 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines
US20030207873A1 (en) * 2002-04-10 2003-11-06 Edmund Harrington Inhibitors of Src and other protein kinases
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
JP4570955B2 (ja) * 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
US20040023977A1 (en) * 2002-07-15 2004-02-05 Larsen Robert D. Process for making substituted thiazolyl-amino pyrimidinyl
ATE381546T1 (de) * 2002-08-24 2008-01-15 Astrazeneca Ab Pyrimidinderivate als modulatoren der aktivitut von chemokinrezeptoren
WO2004105764A1 (en) * 2003-06-02 2004-12-09 Astrazeneca Ab (3- ((quinazolin-4-yl) amino )-1h-pyrazol-1-yl) acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer
DE602004022187D1 (de) * 2003-10-17 2009-09-03 Astrazeneca Ab 4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs
CN100554264C (zh) * 2003-11-24 2009-10-28 弗·哈夫曼-拉罗切有限公司 吡唑基与咪唑基嘧啶
WO2005068468A2 (en) * 2003-12-02 2005-07-28 Vertex Pharmaceuticals, Inc. Heterocyclic protein kinase inhibitors and uses thereof
US7336923B2 (en) * 2003-12-03 2008-02-26 Intel Corporation Method, apparatus and system for extending wireless network coverage
AR049418A1 (es) * 2004-02-27 2006-08-02 Bayer Pharmaceuticals Corp Derivados de heteroarilaminopirazol y composiciones farmaceuticas para el tratamiento de la diabetes.
ATE479687T1 (de) * 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
AU2005316599A1 (en) * 2004-12-14 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrimidine inhibitors of ERK protein kinase and uses therof
WO2006074057A2 (en) * 2004-12-30 2006-07-13 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CN101107245A (zh) * 2005-01-19 2008-01-16 神经能质公司 经杂芳基取代的哌嗪-吡啶类似物
EP1863797A1 (en) * 2005-03-23 2007-12-12 AstraZeneca AB 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY
GB0506886D0 (en) * 2005-04-05 2005-05-11 Astrazeneca Ab Chemical compounds
US7405213B2 (en) * 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7402582B2 (en) * 2005-07-01 2008-07-22 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7442700B2 (en) * 2005-07-01 2008-10-28 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
JP2009504771A (ja) * 2005-08-18 2009-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド ピラジンキナーゼ阻害剤
CA2622352C (en) * 2005-09-30 2014-05-27 Miikana Therapeutics, Inc. Substituted pyrazole compounds
WO2007056163A2 (en) * 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CN101360740A (zh) * 2005-11-16 2009-02-04 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶
UY30444A1 (es) * 2006-06-30 2008-01-31 Astrazeneca Ab Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.

Similar Documents

Publication Publication Date Title
JP2010529193A5 (enExample)
US12209098B2 (en) N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
JP6991213B2 (ja) Ｈｂｖ感染の治療のための新規治療薬
AU2020276277B2 (en) Triaryl compounds for treatment of PD-L1 diseases
CN109415360B (zh) 用于抑制shp2活性的化合物和组合物
JP2025525406A (ja) ピリド［４，３－ｄ］ピリミジン化合物
AU2014277506B2 (en) Bisulfate of Janus kinase (JAK) inhibitor and preparation method therefor
JP2008512348A5 (enExample)
JP2021138737A (ja) プロテインキナーゼ阻害剤及びその調製方法と医薬用途
KR20070102693A (ko) 피리도(3,2-ｄ)피리미딘 및 의학 치료에 유용한 이것의약학적 조성물
JP2006526025A5 (enExample)
KR20170131650A (ko) 글루타미나제 억제제의 투여 방법
JPH07502742A (ja) Ｐａｆ−レセプタ拮抗剤としてのアミノ酸誘導体
DE69219807T2 (de) Thienopyridinderivate und diese enthaltende pharmazeutische Zubereitungen
JP2005538134A5 (enExample)
CA2846695A1 (en) Novel soft rock inhibitors
CA3110474A1 (en) Highly active sting protein agonist compound
CN106589055A (zh) 取代的细胞酰二肽类化合物及其制备方法和用途
RU2010133979A (ru) Синтез лактонов резорциловой кислоты, используемых в качестве терапевтических агентов
JP6948398B2 (ja) キナーゼ阻害剤としてのアミド化合物
JP2005522439A5 (enExample)
JP2007529426A5 (enExample)
US20190202826A1 (en) Phosphotidylinositol 3-Kinase Inhibitors
JP6913955B2 (ja) ＰＩ３Ｋ／ｍＴＯＲ阻害剤としての溶融キノリン化合物
JP2002514578A5 (enExample)